MX2024011298A - Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1 - Google Patents

Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1

Info

Publication number
MX2024011298A
MX2024011298A MX2024011298A MX2024011298A MX2024011298A MX 2024011298 A MX2024011298 A MX 2024011298A MX 2024011298 A MX2024011298 A MX 2024011298A MX 2024011298 A MX2024011298 A MX 2024011298A MX 2024011298 A MX2024011298 A MX 2024011298A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
muc16
combination
epithelioid sarcoma
Prior art date
Application number
MX2024011298A
Other languages
English (en)
Spanish (es)
Inventor
Barcellos Goncalves Priscila Hermont
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024011298A publication Critical patent/MX2024011298A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024011298A 2022-03-17 2024-09-13 Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1 MX2024011298A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320961P 2022-03-17 2022-03-17
US202263350503P 2022-06-09 2022-06-09
PCT/US2023/015347 WO2023177772A1 (en) 2022-03-17 2023-03-16 Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
MX2024011298A true MX2024011298A (es) 2024-12-06

Family

ID=86054295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011298A MX2024011298A (es) 2022-03-17 2024-09-13 Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1

Country Status (9)

Country Link
EP (1) EP4493280A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509567A (cg-RX-API-DMAC7.html)
KR (1) KR20240159849A (cg-RX-API-DMAC7.html)
CN (1) CN119677534A (cg-RX-API-DMAC7.html)
AU (1) AU2023236126A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245946A1 (cg-RX-API-DMAC7.html)
IL (1) IL315405A (cg-RX-API-DMAC7.html)
MX (1) MX2024011298A (cg-RX-API-DMAC7.html)
WO (1) WO2023177772A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202617776A (zh) * 2024-07-10 2026-05-01 美商再生元醫藥公司 治療smarcb1缺陷型癌症之方法
CN119632993B (zh) * 2024-12-04 2025-09-23 安徽医科大学 他泽司他在制备治疗急性肾损伤的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
JP7743314B2 (ja) * 2019-06-21 2025-09-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Also Published As

Publication number Publication date
WO2023177772A1 (en) 2023-09-21
EP4493280A1 (en) 2025-01-22
KR20240159849A (ko) 2024-11-06
IL315405A (en) 2024-11-01
CA3245946A1 (en) 2023-09-21
AU2023236126A1 (en) 2024-09-19
CN119677534A (zh) 2025-03-21
JP2025509567A (ja) 2025-04-11

Similar Documents

Publication Publication Date Title
CL2020003256A1 (es) Métodos para el tratamiento del cáncer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecíficos.
MA44146B1 (fr) Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2022002555A1 (es) Anticuerpos anti-ccr8 para el tratamiento del cáncer
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
CL2021002645A1 (es) Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos. (divisional de solicitud 201900726)
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
CL2021000131A1 (es) Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos.
PE20191661A1 (es) Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
MX2021013815A (es) Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer.
MX2024008055A (es) Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1.
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
PE20230839A1 (es) Agentes de union a lair-1 y metodos para su uso
PE20230374A1 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso
MX2025001239A (es) Métodos para tratar cáncer de próstata resistente a la castración metastasico con anticuerpos biespecíficos anti-psma x anti-cd28 en combinación con anticuerpos anti-pd-1
MX2024014019A (es) Métodos para el tratamiento del cáncer de próstata resistente a la castración metastásico con anticuerpos biespecíficos anti-psma x anti-anticuerpos de cd3 solos o en combinación con anticuerpos anti-pd-1
MX2021009533A (es) Composiciones y metodos para usar anticuerpos bispecificos para unirse al complemento y a un antigeno objetivo.
MX2025010746A (es) Metodos de tratamiento del cancer con moleculas biespecificas anti-cd22 x anti-cd28
MX2022014734A (es) Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.
MX2025012459A (es) Métodos para tratar el mieloma múltiple
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
MX2024006187A (es) Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4.
IL315405A (en) Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies
AR125857A1 (es) ANTICUERPOS PARA EL TRATAMIENTO DE a-SINUCLEINOPATÍAS
AR134210A1 (es) Agentes de unión anti-c2 y conjugados de estos